Q-omics provides the consensus-scored RRN3P2 profile across patient tissues and cancer cell-line models. RRN3P2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RRN3P2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RRN3P2 RNA expression shows 17,498 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where RRN3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRN3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRN3P2 survival associations across molecular data types. RRN3P2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRN3P2 RNA expression–survival associations across cancer types. High RRN3P2 expression shows unfavorable associations in KIRC, GBM, LGG, KIRP and COAD, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RRN3P2 RNA expression.
This table summarizes RRN3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RRN3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRN3P2 shows lower tumor expression in KICH, LUSC, BLCA and UCEC and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher RRN3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.714, t-test p < 0.001).
This table shows molecular features associated with RRN3P2 in patient tissues and cancer cell lines. In patient samples, RRN3P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRN3P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
